摘要
目的观察分析米力农治疗高龄肺心病心力衰竭患者的临床疗效及安全性。方法选择我院2012年9月～2014年8月收治的高龄肺心病心力衰竭患者92例,随机分为研究组和对照组,每组46例。对照组采用常规内科方法进行治疗,研究组在对照组的基础上联合米力农进行治疗,比较两组临床疗效、治疗前后Pa O2、Pa CO2以及血pH值,并评价用药安全性。结果研究组总有效率为89.13%,高于对照组的73.91%,差异有统计学意义（P〈0.05）;与对照组治疗后比较,研究组治疗后Pa O2、Pa CO2以及血pH值改善更为显著,差异有统计学意义（P〈0.05）;两组在治疗期间均未见严重不良反应发生。结论米力农治疗高龄肺心病心力衰竭患者可以有效的改善患者的血气分析指标,取得满意的临床疗效,安全性较好。
Objective To observe the clinical efficacy and safety of milrinone in treatment of elderly patients with pulmonary heart disease heart failure.Methods 92 aged patients with heart failure in our hospital from September 2012 to 2014 August were randomly divided into study group and control group,46 cases in each group.The control group was treated with conventional medical treatment,study group on the basis of the control group of milrinone combined with treatment,clinical curative effect was compared between the two groups,treatment and Pa O2,Pa CO2 and blood pH,and evaluation of the drug safety.Results In the study group,the total effective rate was 89.13%,significantly higher than the control group of 73.91%,the difference is statistically significant（P〈0.05）,and compared with the control group,study group after the treatment of Pa O2,Pa CO2 and blood pH improved more significantly,the difference was statistically significant（P〈0.05）,the two groups during treatment had no serious adverse reactions.Conclusion Milrinone in treatment of senile pulmonary heart disease and heart failure patients can effectively improve the patient＇s blood gas analysis index and achieve satisfactory clinical efficacy,safety is good.
出处
《中国继续医学教育》
2015年第17期159-160,共2页
China Continuing Medical Education
关键词
米力农
高龄
肺心病
心力衰竭
疗效
安全性
Milrinone
Elderly
Pulmonary heart disease
Heart failure
Efficacy
Safety
